Endo to acquire Boca for $225 million
News
Endo Health Solutions announced yesterday that its generics subsidiary, Qualitest, is to acquire privately held Boca Pharmacal for $225 million in cash.
Boca Pharmacal is a specialty generics company that focuses on niche areas, including controlled substances, semisolid drugs and solutions. Endo believes the acquisition will 'accelerate the growth of Qualitest in 2014'.
"The acquisition of Boca Pharmacal is the first of several transactions we plan to execute as we transform Endo into a more focused specialty healthcare company with a lean operating model, able to deliver consistent earnings and revenue growth for our shareholders."
Rajiv De Silva, president and CEO of Endo.
Related news:
Endo's Qualitest unit snags niche generics player for $225M (FiercePharma)
Endo Health to buy private generic drugs firm for $225 million (Reuters)
Reference links:
Endo to Acquire Specialty Generics Company Boca Pharmacal (Press release)
